 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H25IN2O |
| Molar mass | 424.326 g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
RTI-229, also known as(–)-3β-(4-iodophenyl)tropane-2β-pyrrolidine carboxamide andRTI-4229-229, is a potent and long-lastingstimulant drug which was developed in the 1990s as part of a large group of related analogues from thephenyltropane family. With the combination of two potentdopamine transporter (DAT) binding motifs attached to thetropane ring, the p-iodophenyl group at the 3β-position and apyrrolidinecarboxamide at 2β, RTI-229 has extremely high selectivity for the dopamine transporter (2600x and 4600x selective overNET and5-HTT respectively) and is one of the most DAT-selective compounds in the RTI series.[1][2]
RTI-229 is mainly used in scientific research into thedopamine reuptake transporter, with its extremely high DAT selectivity making it useful for distinguishing between DAT and NET binding sites in the brain to an even greater extent than related compounds such asRTI-121.[3]
RTI-229 is legal throughout the world as of 2010. Some jurisdictions such as the United States, Australia and New Zealand might however consider RTI-229 to be acontrolled substance analogue ofcocaine on the grounds of its related chemical structure.
